首页> 外文会议>International Symposium on Current Progress in Mathematics and Sciences >Identification of Novel Ebola Virus (EBOV) VP24 Inhibitor from Indonesian Natural Products through In Silico Drug Design Approach
【24h】

Identification of Novel Ebola Virus (EBOV) VP24 Inhibitor from Indonesian Natural Products through In Silico Drug Design Approach

机译:鉴定INNONESian天然产物通过硅药设计方法从印度尼西亚天然产物的新型埃博拉病毒(EBOV)VP24抑制剂

获取原文

摘要

Ebola remains as one of the deadliest diseases in the world, with almost 29,000 cases were reported and kill 11,000 of them, and yet neither treatment nor vaccine that can combat this disease effectively. This disease is caused by ebolavirus (EBOV), a primary member of Filoviridae family. The life cycle of this virus has been operated by several key proteins, one of them is VP24 protein, which has been known for its crucial role in the transcription and replication of EBOV. Therefore, targeting VP24 protein can be a solution for treating this pathogenic disease. In this study, virtual screening of Indonesian natural products as EBOV VP24 inhibitor was performed. About 2,020 ligands from many sources, including HerbalDB database, were obtained and screened by using DataWarrior software to measure its molecular and pharmacological properties, resulting 301 ligands in the process. Then, the molecular docking simulation was performed to check the ligand's binding interaction and affinity with EBOV VP24 protein; this simulation was done by using MOE 2014.09 software. This study resulted that cycloartocarpin was the best ligand to inhibit the EBOV VP24 protein. Therefore, this ligand should be checked its stability through molecular dynamics simulation and performed in vitro test to verify its bioactivity against the EBOV VP24 protein.
机译:埃博拉仍然是世界上最致命的疾病之一,据报道近29,000例,其中11,000例杀死了11,000例,但既不能有效地打击这种疾病的治疗和疫苗。这种疾病是由埃博拉病毒(EBOV),脲蓟艺家族的主要成员引起的。该病毒的生命周期已被几个关键蛋白操作,其中一个是VP24蛋白,这已在EBOV转录和复制中以其至关重要的作用而闻名。因此,靶向VP24蛋白可以是治疗这种致病性疾病的溶液。在本研究中,进行了印度尼西亚天然产品作为EBOV VP24抑制剂的虚拟筛选。通过使用DataWarrior软件来获得和筛选来自许多来源的2,020个配体,包括米尔巴达数据库,以测量其分子和药理学性质,在该过程中得到301个配体。然后,进行分子对接模拟以检查配体的结合相互作用和与EBOV VP24蛋白的亲和力;该模拟是通过使用MOE 2014.09软件完成的。该研究导致环脂素是抑制EBOV VP24蛋白的最佳配体。因此,该配体应通过分子动力学模拟检查其稳定性,并在体外测试中进行,以验证其对EBOV VP24蛋白的生物活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号